ClinicalTrials.gg
CompletedNCT03432364Updated Dec 14, 2023Results posted

A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)

A Phase 1/2 interventional study of ST-400 Investigational product in Transfusion Dependent Beta-thalassemia, sponsored by Sangamo Therapeutics. Completed at 6 sites in United States. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2023-12-14.

Sponsored by Sangamo Therapeutics · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 91 studies in beta-Thalassemia with a site in United States — 22 open to participants now, 36 under way, 8 of them phase 3. beta-Thalassemia · United States.

Enrollment
64th of 71
5 · median 25
Started
2018
with 5 others
Phase 1/2
11 of 91
3 open now
Registered
52nd of 91
by date

Among the 91 studies in beta-Thalassemia with a site in United States, this one is the 64th largest by enrollment of the 71 interventional ones that give a count, is one of 6 that started in 2018, is one of 11 in phase 1/2, and was the 52nd registered.

beta-Thalassemia

294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

22 of the 91 studies in beta-Thalassemia with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 22 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 40 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in beta-Thalassemia with a site in United States, or all of them as a file.
02

Study summary

This is a single-arm, multi-site, single-dose, Phase 1/2 study to assess ST-400 in 6 subjects with transfusion-dependent β-thalassemia (TDT) who are ≥18 and ≤40 years of age. ST-400 is a type of investigational therapy that consists of gene edited cells. ST-400 is composed of the patient's own blood stem cells which are genetically modified in the laboratory using Sangamo's zinc finger nuclease (ZFN) technology to disrupt a precise and specific sequence of the enhancer of the BCL11A gene (which normally suppresses fetal hemoglobin production in erythrocytes). This process is intended to boost fetal hemoglobin (HbF), which can substitute for reduced or absent adult (defective) hemoglobin. ST-400 is then infused back into the patient after receiving conditioning chemotherapy to make room for the new cells in the bone marrow, with the aim of producing new erythrocytes with increased amounts of HbF. The primary objective is to understand safety and tolerability of ST-400, and secondary objectives are to assess the effects on HbF levels and transfusion requirements.

Read the detailed description

Once consented, study participants will progress through the following stages:

  • Screening: in-person visit at the study site to confirm eligibility for proceeding
  • Collection: autologous (self) blood stem cells are harvested at the study site, also known as apheresis
  • Manufacturing of ST-400: no study participant activities expected
  • Infusion: conditioning chemotherapy, followed by infusion of ST-400, occurs at the study site
  • Follow-up: follow up at the study site to monitor for safety and effectiveness of the study
03

Conditions studied

  • Transfusion Dependent Beta-thalassemia

Browse trials for

Keywords

  • Beta thalassemia
  • Beta-thalassemia
  • Thalassemia major
  • Cooley's anemia
  • ZFN mediated genome editing
  • zinc finger nuclease
04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Clinical diagnosis of TDT with ≥ 8 documented RBC transfusion events per year on an annualized basis in the 2-years prior to screening
  2. Confirmed beta-thalassemia diagnosis by molecular genetic testing
  3. Clinically stable and eligible to receive conditioning chemotherapy
  4. Able and willing to use an effective method of from the signing of the informed consent and for one year following ST-400 infusion.

Exclusion criteria

Exclusion Criteria:

  1. Previous history of or allogeneic blood stem cell transplantation or solid organ transplantation
  2. Pregnant or breastfeeding female
  3. Medical to mobilization, apheresis, or conditioning
  4. Significant liver, lung, heart, or kidney dysfunction
  5. Diagnosis of or evidence of active or
  6. History of significant bleeding disorder or uncontrolled seizures
  7. History of active in past 5 years (non-melanoma skin cancer or cervical cancer in situ permitted) any history of hematologic malignancy, or family history of cancer predisposition syndrome without negative testing result in the study candidate.
  8. Currently participating in another clinical trial using an study medication, or recent participation in such a trial
  9. Previous treatment with gene therapy
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    ST-400 Investigational product

    ST-400 Investigational product is composed of autologous CD34+ hematopoietic stem/progenitor cells that are genetically modified ex vivo at the erythroid-specific enhancer of the BCL11A gene

    Genetic: ST-400 Investigational product

Interventions

  • GeneticST-400 Investigational product

    Single dose of ST-400 following chemotherapy conditioning with busulfan

06

What researchers measure

Primary outcomes

  1. Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 156 Weeks After the ST-400 Infusion

    Safety and tolerability assessed by number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 156 weeks after the ST-400 infusion

    Time frame: Up to 156 weeks after the ST-400 infusion

Secondary outcomes

  1. Clinical Laboratory Measurement of Hemoglobin (Hb) Fractions (A and F in g/dL)

    Change from baseline clinical laboratory measurement of Hb fractions (A and F in g/dL) \[Time Frame: Up to 156 weeks after ST-400 infusion\]

    Time frame: Baseline, Weeks 26, 52, and 156 after ST-400 infusion

  2. Clinical Laboratory Measurements of Percent (%) HbF

    Change from baseline percent (%) HbF \[Time Frame: Up to 156 weeks after ST-400 infusion\]

    Time frame: Baseline, Weeks 26, 52, and 156 after ST-400 infusion

  3. Annualized Frequency of Packed RBC Transfusions

    Calculation of annualized frequency and volume of packed red blood cell (PRBC) transfusions after ST-400 infusion transfusion support in the 2 years prior to screening

    Time frame: From Baseline (2 years prior to screening/consent), to ST-400 Infusion (Day 0), after hematopoietic reconstitution and up to 156 weeks (post ST-400 infusion)

  4. Annualized Volume (mL) of Packed RBC Transfusions

    Historical baseline defined as transfusion support in the 2 years prior to screening.

    Time frame: From Baseline (2 years prior to screening/consent), to ST-400 Infusion (Day 0), after hematopoietic reconstitution and up to 156 weeks (post ST-400 infusion)

07

Results

Posted Dec 13, 2023
Limitations and caveats
Due to the limited sample size of 5 subjects, the study results presented are primarily descriptive in nature.

Participant flow

The original enrollment goal was six subjects were to be enrolled in the Phase 1/2 study ST-400-01, but 5 subjects were enrolled and dosed. One subject from the 5 dosed withdrew consent prior to completing the study. Subjects who received treatment with ST-400 were asked to participate in a separate observational long-term safety study.

Primary (ST-400 Infusion up to Week 52 )
Participant flow — Primary (ST-400 Infusion up to Week 52 )
MilestoneST-400 Investigational Product
Started5
Completed5
Not completed0
Follow Up (Weeks 52-156 Post Infusion)
Participant flow — Follow Up (Weeks 52-156 Post Infusion)
MilestoneST-400 Investigational Product
Started5
Completed4
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryParticipants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 156 Weeks After the ST-400 Infusion

Safety and tolerability assessed by number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 156 weeks after the ST-400 infusion

Time frame:
Up to 156 weeks after the ST-400 infusion
Reported as:
Number · participants
Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) up to 156 Weeks After the ST-400 Infusion
participantsST-400 Investigational Product
Incidence of non-serious adverse events5
Incidence of serious adverse events2
SecondaryClinical Laboratory Measurement of Hemoglobin (Hb) Fractions (A and F in g/dL)

Change from baseline clinical laboratory measurement of Hb fractions (A and F in g/dL) \[Time Frame: Up to 156 weeks after ST-400 infusion\]

Time frame:
Baseline, Weeks 26, 52, and 156 after ST-400 infusion
Reported as:
Mean · g/dL
Clinical Laboratory Measurement of Hemoglobin (Hb) Fractions (A and F in g/dL)
g/dLST-400 Investigational Product
Hemoglobin A (g/dL) Change from Baseline to Week 26-3.648 ± 2.0401
Hemoglobin A (g/dL) Change from Baseline to Week 52-3.227 ± 2.0789
Hemoglobin A (g/dL) Change from Baseline to Week 156-0.281 ± 1.5834
Hemoglobin F (g/dL) Change from Baseline to Week 261.025 ± 1.0898
Hemoglobin F (g/dL) Change from Baseline to Week 520.405 ± 0.2851
Hemoglobin F (g/dL) Change from Baseline to Week 1560.502 ± 0.2936
SecondaryClinical Laboratory Measurements of Percent (%) HbF

Change from baseline percent (%) HbF \[Time Frame: Up to 156 weeks after ST-400 infusion\]

Time frame:
Baseline, Weeks 26, 52, and 156 after ST-400 infusion
Reported as:
Mean · Percentage of Hemoglobin F
Clinical Laboratory Measurements of Percent (%) HbF
Percentage of Hemoglobin FST-400 Investigational Product
Week 2612.83 ± 14.282
Week 525.30 ± 3.188
Week 1564.35 ± 3.040
SecondaryAnnualized Frequency of Packed RBC Transfusions

Calculation of annualized frequency and volume of packed red blood cell (PRBC) transfusions after ST-400 infusion transfusion support in the 2 years prior to screening

Time frame:
From Baseline (2 years prior to screening/consent), to ST-400 Infusion (Day 0), after hematopoietic reconstitution and up to 156 weeks (post ST-400 infusion)
Reported as:
Mean · PRBC transfusions/year
Annualized Frequency of Packed RBC Transfusions
PRBC transfusions/yearST-400 Investigational Product
Baseline transfusion support 2 years prior to screening/consent17.393 ± 5.4350
At ST-400 Infusion (Day 0)21.518 ± 4.8806
After hematopoietic reconstitution (up to 156 weeks after ST-400 infusion)19.665 ± 5.6716
SecondaryAnnualized Volume (mL) of Packed RBC Transfusions

Historical baseline defined as transfusion support in the 2 years prior to screening.

Time frame:
From Baseline (2 years prior to screening/consent), to ST-400 Infusion (Day 0), after hematopoietic reconstitution and up to 156 weeks (post ST-400 infusion)
Reported as:
Mean · mL/year
Annualized Volume (mL) of Packed RBC Transfusions
mL/yearST-400 Investigational Product
Baseline transfusion support 2 years prior to screening/consent10295.984 ± 4063.3661
At ST-400 infusion (Day 0)7453.191 ± 4204.3456
After hematopoietic reconstitution (up to 156 weeks after ST-400 infusion)7068.788 ± 4480.8901

Adverse events

Collected over Participants with adverse events data collected from ICF signed through participant's last study visit, up to 156 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ST-400 Investigational Product0/5 (0%)3/5 (60%)5/5 (100%)
Most frequent serious events
Most frequent serious events
EventST-400 Investigational Product
Drug withdrawal syndromeGeneral disorders1/5
HypersensitivityImmune system disorders1/5
PneumoniaInfections and infestations1/5
Most frequent other events
Showing 10 of 92
Most frequent other events
EventST-400 Investigational Product
NauseaGastrointestinal disorders5/5
ArthralgiaMusculoskeletal and connective tissue disorders5/5
InsomniaPsychiatric disorders5/5
Febrile neutropeniaBlood and lymphatic system disorders4/5
AnaemiaBlood and lymphatic system disorders4/5
ConstipationGastrointestinal disorders4/5
StomatitisGastrointestinal disorders4/5
NeutropeniaBlood and lymphatic system disorders3/5
ThrombocytopeniaBlood and lymphatic system disorders3/5
DiarrhoeaGastrointestinal disorders3/5

Baseline characteristics

The study population comprise male and non-pregnant, non-lactating female subjects with TDT between 18 and 40 years old, who are willing and able to undergo autologous HSCT.

Age, Continuous
Age, Continuous(years)ST-400 Investigational Product
Mean28.4 ± 7.77
Sex: Female, Male
Sex: Female, Male(Participants)ST-400 Investigational Product
Sex — Female2
Sex — Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ST-400 Investigational Product
Hispanic or Latino1
Not Hispanic or Latino4
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ST-400 Investigational Product
American Indian or Alaska Native0
Asian3
Native Hawaiian or Other Pacific Islander0
Black or African American0
White2
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)ST-400 Investigational Product
United States5
Hemoglobin A (g/dL) at Baseline
Hemoglobin A (g/dL) at Baseline(g/dL)ST-400 Investigational Product
Mean11.040 ± 0.6006
Hemoglobin F (g/dL) at Baseline
Hemoglobin F (g/dL) at Baseline(g/dL)ST-400 Investigational Product
Mean0.169 ± 0.0835
Hemoglobin F Percentage at Baseline
Hemoglobin F Percentage at Baseline(Percentage)ST-400 Investigational Product
Mean1.48 ± 0.760
08

Study locations

6 sites
  • University of California, Los Angeles
    Los Angeles, California 90095-1678, United States
  • UCSF Benioff Children's Hospital Oakland
    Oakland, California 94609, United States
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30322, United States
  • Dana-Farber Boston Children's Cancer and Blood Disorders Center
    Boston, Massachusetts 02116, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
09

References and documents

Publications

  • Brusson M, Miccio A. Genome editing approaches to beta-hemoglobinopathies. Prog Mol Biol Transl Sci. 2021;182:153-183. doi: 10.1016/bs.pmbts.2021.01.025. Epub 2021 Mar 1. PubMed 34175041 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Nov 2022, 55 months.

Results were first posted in Dec 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2018
First posted
Feb 14, 2018
StartActual
Mar 29, 2018
Primary completionActual
Nov 17, 2022
CompletionActual
Nov 17, 2022
Results first posted
Dec 13, 2023
Last update
Dec 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03432364
Responsible party
Sponsor
First posted
Feb 14, 2018
Start date
Mar 29, 2018
Primary completion
Nov 17, 2022
Completion
Nov 17, 2022
Results posted
Dec 13, 2023
Last update
Dec 14, 2023

Study contacts

Medical Monitor
study director · Sangamo Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion